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Acute hyperglycemia enhances oxidative stress and exacerbates
myocardial infarction by activating nicotinamide adenine
dinucleotide phosphate oxidase during reperfusion
Zequan Yang, MD,a Victor E. Laubach, PhD,a Brent A. French, PhD,b and Irving L. Kron, MDa
Objective: Acute hyperglycemia is independently associated with larger myocardial infarct size in both diabetic
and nondiabetic patients. We hypothesized that the oxidative stress imposed by acute hyperglycemia contributes
to the exacerbation of infarct size during reperfusion.
Methods: C57BL/6 mice underwent 30 minutes of occlusion of the left anterior descending coronary artery
followed by 60 minutes of reperfusion. Acute hyperglycemia was induced with an intraperitoneal injection of
dextrose (2g/kg body weight) 30 minutes before left anterior descending occlusion. An antioxidant, N-2-mercap-
topropionyl glycine, was injected intravenously 2 minutes before the onset of reperfusion at a dose of 20 mg/kg. A
nicotinamide adenine dinucleotide phosphate oxidase inhibitor, apocynin (50 mg/kg), was applied either before
or after the induction of hyperglycemia.
Results: Blood glucose level before left anterior descending occlusion was 153  19 mg/dL in control mice and
444  26 mg/dL in hyperglycemic mice (P< .05). Plasma lipid peroxidation product (malondialdehyde) was
significantly increased in both control and hyperglycemic mice at 1 hour after reperfusion, and levels of malon-
dialdehyde in hyperglycemic mice were higher than that in control mice (3.38 0.21 vs 2.33 0.12 mmol/L; P<
.05). N-2-mercaptopropionyl glycine administered just before reperfusion significantly reduced malondialdehyde
levels in both control and hyperglycemic mice (1.21  0.06 and 1.03  0.24 mmol/L). Acute hyperglycemia
increased infarct size (percent of risk region) from 34.0  2.7 to 49.4  1.6 (P< .05). N-2-mercaptopropionyl
glycine reduced infarct size to 19.5  2.3 in control mice and to 26.2  2.9 in hyperglycemic mice. Apocynin
also reduced malondialdehyde levels and infarct size in hyperglycemic mice if administered 5 minutes before
injection of dextrose, but not before reperfusion.
Conclusion: Acute hyperglycemia enhances oxidative stress and exacerbates myocardial infarction in mice
through activation of nicotinamide adenine dinucleotide phosphate oxidase.
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PReperfusion injury after cardioplegic arrest exists even
with optimal cardioprotective strategy. Hyperglycemia is
commonly present in the perioperative period in patients
undergoing cardiac surgery.1-3 Hyperglycemia during car-
diopulmonary bypass is an independent risk factor for mor-
tality and morbidity both in patients with diabetes mellitus
and in those without.3 However, the significance of hyper-
glycemia in the nondiabetic patient undergoing cardiac sur-
gery and the potential benefits of glucose–insulin–potassium
infusion are still the subject of intense debate.1 An increas-
ing body of clinical evidence has shown that acute hypergly-
cemia (or stress hyperglycemia) is independently associated
with larger myocardial infarct size and impaired left ventric-
ular function in both diabetic and nondiabetic patients.4,5
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dial infarction (MI), even in the absence of a history of dia-
betes. In one recent study of 1664 patients with acute MI,
more than 25% had acute hyperglycemia on admission,
but more than 30% of these patients had no history of diabe-
tes.6 Moreover, animal studies have shown that the size of
the MI increases in response to elevations in blood glucose
levels7 and that acute hyperglycemia counteracts the cardio-
protective effects of ischemic and pharmacologic precondi-
tioning.8,9 Although the hyperglycemic exacerbation of MI
has become the subject of increasing research, little is known
about the mechanisms underlying this phenomenon.
Acute hyperglycemia is known to decrease endothelial ni-
tric oxide production, thus impairing normal vascular func-
tion,10-12 adversely affecting coronary microcirculation,13
and markedly attenuating signal transduction pathways crit-
ical to endogenous cardioprotective responses.8 A recent
study shows that pharmacologic preconditioning against
MI in the setting of acute hyperglycemia can be restored
by N-acetylcysteine (a potent antioxidant),14 suggesting
a possible role for oxidative stress in the acute hyperglyce-
mic exacerbation of MI.
In the current study, acute hyperglycemia was created
in mice by intraperitoneal injection of concentrated dex-
trose before the scheduled ischemia/reperfusion injury.ardiovascular Surgery c Volume 137, Number 3 723
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PAbbreviations and Acronyms
LAD ¼ left anterior descending coronary artery
MDA ¼ malondialdehyde
MI ¼ myocardial infarction
MPG ¼ N-2-mercaptopropionyl glycine
NADPH ¼ nicotinamide adenine dinucleotide
phosphate
ROS ¼ reactive oxygen species
RR ¼ risk region
TTC ¼ triphenyl tetrazolium chloride
We hypothesized that the exacerbation of MI by acute
hyperglycemia is due to oxidative stress resulting from the
activation of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase.
MATERIALS AND METHODS
This study conformed to the ‘‘Guide for the Care and Use of Laboratory
Animals’’ published by the National Institutes of Health (NIH publication
No. 85-23, revised 1985) and was conducted under protocols approved by
the University of Virginia’s Institutional Animal Care and Use Committee.
Agents and Chemicals
Triphenyl tetrazolium chloride (TTC), N-2-mercaptopropionyl glycine
(MPG), and apocynin were purchased from Sigma-Aldrich (St Louis,
Mo). Phthalo blue was purchased from Heucotech Ltd (Fairless Hills, Pa).
Animals and Experimental Protocol
Sixty-three C57BL/6 mice (8–12 weeks old, purchased from Jackson
Laboratories, Bar Harbor, Maine) were used in this study. Of these mice,
5 were used for dextrose dosing study to create acute hyperglycemia. An-
other 3 mice underwent left thoracotomy as sham controls. The rest of the
mice were assigned to 6 different groups and underwent 30 minutes of is-
chemia and 60 minutes of reperfusion, as shown in Figure 1. Acute hyper-
glycemia was induced by intraperitoneal injection of 20% dextrose 30
minutes before occlusion of the left anterior descending coronary artery
(LAD) at a dose of 10 mL/g body weight (HGmice). In control mice, normal
saline was given by intraperitoneal injection 30 minutes before LAD occlu-
sion at a dose of 10 mL/g body weight. In MPG-treated mice, MPG (10 mg/
mL in phosphate-buffered saline solution) was administered 2 minutes be-
fore reperfusion by intravenous injection at a dose of 2 mL/g. In apocynin-
treated mice, apocynin (APO; 5 mg/mL in 5% ethanol) was administered at
a dose of 2 mL/g either intravenously 5 minutes before reperfusion in
HGþAPO mice or intraperitoneally 5 minutes before induction of hypergly-
cemia in APOþHG mice (Figure 1).
Myocardial Ischemia/Reperfusion Injury and
Measurement of Infarct Size
Mice were subjected to 30 minutes of coronary occlusion followed by 60
minutes of reperfusion and then humanely killed to evaluate myocardial in-
farct by TTC–phthalo blue staining. A standard protocol was used as de-
tailed previously.15,16 In brief, mice were anesthetized with sodium
pentobarbital (100 mg/kg ip) and orally intubated. Artificial respiration
was maintained with an inspired oxygen fraction of 0.80, 100 strokes per
minute, and a 1.0- to 1.5-mL stroke volume. The heart was exposed through
a left thoracotomy, and coronary artery occlusion was achieved by passing
a suture beneath the LAD and tightening over a piece of polyethylene-60724 The Journal of Thoracic and Cardiovascular Surtubing for 30 minutes. Reperfusion was induced by removal of the polyeth-
ylene-60 tubing. The electrocardiogramwas monitored perioperatively with
PowerLab instrumentation (ADInstruments, Colorado Springs, Colo). The
mice were humanely killed 60 minutes after reperfusion, and the hearts
were cannulated through the ascending aorta for perfusion with 3 to 4 mL
of 1.0% TTC. The LAD was then reoccluded with the same suture used
for coronary occlusion before 10% phthalo blue perfusion to determine
risk region (RR). The left ventricle was then cut into 5 to 7 transverse slices
that were weighed and digitally photographed to determine infarct size as
a percent of RR. Reperfusion for 60 minutes is selected because the infarct
size appears homogeneous at that time and does not become larger with lon-
ger reperfusion periods.17
Measurement of Plasma Malondialdehyde (MDA)
At the end of 1 hour of reperfusion, blood was collected by puncturing
the right ventricle and plasma was obtained after centrifuging the blood at
500g for 8minutes.Malondialdehyde (MDA)wasmeasuredwith a commer-
cial assay kit (Cayman Chemical Company, Ann Arbor, Mich).
Statistical Analysis
All data are presented as the mean standard error of the mean. Peri-is-
chemic heart rate changes were analyzed by a repeated-measures analysis of
variance followed by Bonferroni pairwise comparisons. All other data were
compared by 1-way analysis of variance followed by a t test for unpaired
data with Bonferroni correction.
RESULTS
Perioperative Heart Rate Changes
Table 1 shows changes in heart rate before, during, and
after LAD occlusion. Heart rate was increased significantly
after LAD occlusion and remained tachycardiac until early
reperfusion. There was no significant difference in heart
rate between control and treated mice.
Acute Hyperglycemia in Mice
A preliminary dose range study conducted with a conven-
tional glucose meter (iTest; Auto Control Medical Inc,
Pointe-Claire, Canada) indicated that a single bolus injection
of 20% dextrose (10 mL/g or 2 g dextrose per kilogram body
weight) sufficed to achieve transient blood glucose levels be-
tween 400 and 500 mg/dL. A time course of blood glucose
levels was then evaluated at this dose in a group of 5 C57BL/
6J mice. Before injection, blood glucose in unfasted mice
ranged from 117 to 150 mg/dL (mean, 129  8 mg/dL). Af-
ter injection, blood glucose increased rapidly to a peak at 20
minutes after injection of 442  48 mg/dL, and then gradu-
ally declined while retaining mean levels of over 400 mg/dL
for a period of 20minutes (Figure 2). Blood glucose returned
to baseline 2 hours after dextrose injection. Table 1 shows
the blood glucose levels before LAD occlusion in all of
the experimental groups, demonstrating that the hyperglyce-
mic mice had significantly higher blood glucose levels than
the other groups.
Acute Hyperglycemia Enhances Oxidative Stress and
Exacerbates MI
Four groups of mice (Figure 1, top 4 groups) underwent
30 minutes of LAD occlusion followed by 60 minutes ofgery c March 2009
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Preperfusion, and an additional sham group underwent tho-
racotomy without LAD occlusion. A potent antioxidant,
MPG, was administered in MPG-treated groups at a dose
of 20 mg/kg 2 minutes before reperfusion. The mean blood
glucose levels before LAD occlusion were 135  19 mg/
dL in control or 124  13 mg/dL in MPG-treated (MPG
group) and 444  26 mg/dL in untreated hyperglycemic
mice (P< .05, Table 1). In control mice, plasma MDA
was significantly increased during reperfusion compared
with sham-operated mice (2.33  0.12 vs 0.71  0.05
mmol/L; P< .05). Acute hyperglycemia further increased
plasma MDA to 3.38  0.21 mmol/L (P< .05 vs control
or sham). Treatment with MPG significantly reduced
plasma MDA in both control and hyperglycemic mice to
1.21  0.24 mmol/L and 1.03  0.06 mmul/L, respectively
(P<.05 vs either MPG or hyperglycemic groups, Figure 3).
Correspondingly, myocardial infarct size was enhanced by
acute hyperglycemia. There were no statistical differences
in RR size (percent of left ventricle) among the 4 groups
(control, 42.7  1.7; HG, 41.6  1.3; MPG, 37.9  1.8;
HGþMPG: 38.9  1.5). In control mice, infarct size
(percent of RR) was 34.0  2.7. Infarct size in HG mice
increased by 45% to 49.4  1.6 (P< .05 vs control). Ad-
ministration of MPG (MPG group) reduced infarct size to
19.5  2.3 (43% reduction from control). Administration
of MPG to HGþMPG mice reduced infarct size to 30.0 
4.3, a 39% reduction (P < .05 vs HG mice, Figures 4
and 5).
NADPH Oxidase Contributes to Acute
Hyperglycemic Exacerbation of MI
Apocynin, a specific NADPH oxidase inhibitor, was ad-
ministered at a bolus dose of 50 mg/kg body weight either
shortly before the onset of reperfusion intravenously
(HGþAPO) or before induction of hyperglycemia intraperi-
toneally (APOþHG, Figure 1). LAD ligation caused compa-
rable RR in apocynin-treated mice as with other groups
(APOþHG, 37.2  1.4; HGþAPO, 39.3  2.5; P ¼ NS vs
control or HG group). Administration of apocynin before
TABLE 1. Blood glucose levels before LAD occlusion and
perioperative heart rates
Heart rate (beats/min)
Groups
Blood
glucose (mg/dL)
Before
occlusion
During
occlusion Reperfusion
Control 153  19 406  14 443  9y 445  10y
HG 444  26* 407  15 466  18y 448  20
MPG 124  13 408  12 458  11y 428  10
HGþMPG 480  21* 404  6 453  16y 445  13
HGþAPO 422  24* 393  9 451  12y 472  15y
APOþHG 496  16* 395  12 439  7y 430  7y
HG,Hyperglycemia;MPG, N-2-mercaptopropionyl glycine; APO, apocynin. *P<.05
vs control yP< .05 vs before occlusion.
Control
(n=12)
ReperfusionOcclusion
ReperfusionOcclusion
-30min 0 30 90 min
Saline
Dextrose
ReperfusionOcclusion
ReperfusionOcclusion
MPG 20 mg/kg iv
HG
(n=8)
MPG
(n=8)
HG+MPG
(n=8)
MPG 20 mg/kg iv
Saline
Dextrose
ReperfusionOcclusion
APO 50 mg/kg iv
HG+APO
(n=10)
Dextrose
ReperfusionOcclusion
APO+HG
(n=9)
DextroseAPO 50 mg/kg ip
FIGURE 1. Study groups and experiment protocols. HG, Hyperglycemia;
MPG, N-2-mercaptopropionyl glycine; APO, apocynin.
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FIGURE 2. Time course of blood glucose levels after single ip injection of
20% dextrose (10 mL/g body weight). *P< .05 vs baseline (time 0).
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FIGURE 3. Plasma levels of malondialdehyde (MDA) after 30 minutes of
LAD occlusion and after 60 minutes of reperfusion. *P< .05 vs control,
HG, or HGþAPO; #P<0.05 vs sham or HG. HG, Hyperglycemia; MPG,
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Preperfusion (HGþAPO) had no effect on plasmaMDA levels
(3.32 0.18 mmol/L; P¼ not significant [NS] vs HG group)
and correspondingly had no effect on infarct size of hyper-
glycemic mice (45.9  2.8; P ¼ NS vs HG group; P< .05
vs control; Figures 3 to 5). However, administration of apoc-
ynin before the induction of hyperglycemia (APOþHG) sig-
nificantly reduced MDA levels to 1.25  0.46 mmol/L (P<
.05 vs HG or HGþAPO) and abrogated the hyperglycemia-
induced infarct expansion and significantly reduced infarct
size to 26.2  2.9 (P< .05 vs HG: P ¼ NS vs control;
Figures 3 to 5).
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FIGURE 4. Myocardial infarct size after 30 minutes of LAD occlusion and
60 minutes of reperfusion. Acute hyperglycemia exacerbates infarct size.
The hyperglycemic exacerbation of infarct size was completely abrogated
by MPG administered at reperfusion or apocynin administered before hy-
perglycemia. *P<.05 vs HG or HGþAPO; #P<.05 vs control.HG,Hyper-
glycemia; MPG, N-2-mercaptopropionyl glycine; APO, apocynin.Correlation Between Plasma MDA Level and
Myocardial Infarct Size
By pooling the data from all 6 groups of mice, we
found a strong correlation between MDA levels and myo-
cardial infarct size 1 hour after reperfusion, R2 ¼ 0.62
(Figure 6).
DISCUSSION
Through administration of concentrated dextrose, acute
hyperglycemia was created in nondiabetic mice. Acute
hyperglycemia significantly increases the production of
reactive oxygen species (ROS) during reperfusion as char-
acterized by lipid peroxidation products (MDA) in plasma
and thereby exacerbates myocardial infarct size in mice.
The efficacy of MPG in reducing infarct size in hyper-
glycemic mice when administered only minutes before
reperfusion demonstrates that oxidative stress contributes
importantly to the hyperglycemic exacerbation of infarct
size. MPG is a potent ROS scavenger and thus acts on
the end products (ROS) of oxidative stress. Apocynin, a
selective NADPH oxidase inhibitor, similarly inhibited
oxidative stress and protected the heart against the hyper-
glycemic exacerbation of infarct size, but only when it
was applied before the hyperglycemic insults, indicating
that the hyperglycemic oxidative stress involves NADPH
oxidase. Taken together, the results indicate that acute hy-
perglycemia induced in nondiabetic mice shortly before
myocardial ischemia significantly increases oxidative stress
and exacerbates MI in mice through the activation of
NADPH oxidase.FIGURE 5. TTC- and phthalo blue–stained, short-axis tissue sections of left ventricles from representative mice from the 6 groups summarized in Figures 1
and 4. Blue areas are nonischemic tissue, yellowish white areas are infarcted tissue, and red areas represent salvaged (viable) tissue within the previously
ischemic myocardium (risk region).
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PCompelling evidence has shown that acute (or stress) hy-
perglycemia is an independent predictor of cardiovascular
morbidity and mortality, independent of diabetes.3,18-20
Stress hyperglycemia shares many properties with hypergly-
cemia associated with type 2 diabetes, including increased
oxidative stress,21-24 inflammation,25-28 and activation of
stress-responsive kinase.20,26 Infarcts are usually larger in
patients with stress or diabetes-related hyperglyce-
mia,4,5,20,29 and animals with acute hyperglycemia sustain
dramatically larger infarcts after experimental ischemia/
reperfusion than do euglycemic controls.7-9 Increased sensi-
tivity to ischemia/reperfusion injury and more severe
myocardial damage is one reason for the poor prognosis of
patients having acute MI with stress hyperglycemia.
Although the mechanisms underlying acute or stress hy-
perglycemia may differ between patients and animal
models,8,29 hyperglycemia has proven to be an independent
risk factor for larger infarct size,4,5,7,8 and this hyperglyce-
mic infarct exacerbation is not related to increased osmolal-
ity.7 To simulate the stress hyperglycemia seen in human
patients, we similarly induced acute hyperglycemia in
mice in the current study by intraperitoneal injection of con-
centrated dextrose. Sustained hyperglycemia ensued lasting
over 30 minutes. LAD occlusion and reperfusion were per-
formed during this period of hyperglycemia. Blood glucose
levels were 3-fold greater in hyperglycemic mice than in
nonhyperglycemic mice. There was no difference in preop-
erative heart rate between hyperglycemic and nonhypergly-
cemic mice (Table 1). Myocardial ischemia and reperfusion
induced oxidative stress that was documented after reperfu-
sion. Acute hyperglycemia exacerbated this oxidative stress.
Correspondingly, a significantly larger infarct size was
found in hyperglycemic mice. This oxidative stress is posi-
tively correlated with myocardial infarct size (R2 ¼ 0.62;
Figure 6). An ROS scavenger, MPG, significantly reduced
oxidative stress in both control and hyperglycemic mice
and completely abrogated the hyperglycemic exacerbation
R2 = 0.6163
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FIGURE 6. Correaltion between plasma MDA levels and myocardial in-
farct size by pooling the data from different groups. R2 ¼ 0.62.The Journal of Thoracic and Cof infarct size (Figures 3 to 5). To further define the source
of the ROS responsible for the hyperglycemic exacerbation
of infarct size, we applied a selective inhibitor of NADPH
oxidase30 (apocynin) to hyperglycemic mice. Apocynin
proved to be as effective as MPG in completely abrogating
the hyperglycemic oxidative stress and abolishing the hy-
perglycemic exacerbation of infarct size, provided it was
administered before the induction of hyperglycemia. How-
ever, the cardioprotective effect of apocynin was lost when
its application was delayed until after the induction of
hyperglycemia (Figures 4 and 5).
Myocardial ischemia/reperfusion injury is also associated
with oxidative stress in the nondiabetic subjects, as shown in
the current study (Figure 3) and others.31,32 However, the
role of ROS scavenger or NADPH inhibition in reducing
MI remains controversial.33 Acute hyperglycemic exacerba-
tion of myocardial ischemia/reperfusion injury has been
documented in both clinical and animal studies, but the
role of antioxidant therapy in this setting is lacking.
It is widely known that acute or stress hyperglycemia
is associated with oxidative stress and inflammatory
responses.10,21,23,24,26-28 The degree of oxidative stress
correlates most closely with acute, not chronic, glucose fluc-
tuations.24 Oxidative stress is defined in general as excess
formation and/or insufficient removal of highly reactive
molecules such as ROS and reactive nitrogen species. There
are multiple potential sources of oxidative stress during hy-
perglycemia, including nonenzymatic, enzymatic, and mito-
chondrial sources.34 Nonenzymatic sources of oxidative
stress originate from auto-oxidation of glucose or formation
of advanced glycation end products. Enzymatic sources for
the augmented generation of oxidative stress during hyper-
glycemia include nitric oxide synthase, NADPH oxidase,
and xanthine oxidase. The mitochondrial respiratory chain
is another potential source of oxidative stress in this setting.
Although not fully understood, evidence is mounting to sug-
gest that NADPH oxidase plays an important role in mediat-
ing acute hyperglycemic oxidative stress.23,27,34
In the current study, acute hyperglycemia-induced oxida-
tive stress was clearly defined during reperfusion, and this
oxidative stress, as well as the exacerbation in infarct size,
was completely abolished with the use of a potent ROS scav-
enger or NADPH oxidase inhibitor. Interestingly, neither
MPG nor apocynin could reduce infarct size in hyperglyce-
mic mice back to the size found in MPG-treated euglycemic
mice (Figure 4). This may reflect the deleterious effects of
hyperglycemia on the endogenous defense system of cardi-
omyocytes, which makes them sensitive to ischemic in-
jury.7,8,20 Thus antioxidant therapy appears to abrogate the
exacerbation of reperfusion injury, but not ischemic injury.
Apocynin inhibits NADPH oxidase by acting as an irre-
versible inhibitor of the p47phox subunit. Apocynin prevents
the translocation of cytosolic p47phox to Nox2 in the mem-
brane of leukocytes, monocytes, and endothelial cells.35-38ardiovascular Surgery c Volume 137, Number 3 727
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PHowever, the compound requires activation by myeloperox-
idase and/or H2O2
38 to be effective. For this reason, the in-
hibitory action of the compound appears to be most
effective in leukocytes and then only after a lag period.37,38
Although the current experiment did not explore the possible
cellular sources of oxidative stress, an increasing body of ev-
idence indicates that acute or stress hyperglycemia activates
leukocytes that mediate the oxidative stress and inflamma-
tory responses.5,23,26 The cardioprotective effect of apocy-
nin against the hyperglycemic exacerbation of infarct size
is thus probably due to its action on the NADPH oxidases
in leukocytes.
In the current experiments, the antioxidant and cardio-
protective effects of apocynin against the hyperglycemic
exacerbation of infarct size disappeared when it was admin-
istered just before reperfusion. The reason for this may be
2-fold: (1) acute hyperglycemia caused the translocation of
p47phox and activation of NADPH oxidase before the
administration of apocynin and (2) the lag time required
for activation of the compound made it less effective against
hyperglycemia-induced p47phox translocation. Treatment
with apocynin before the induction of hyperglycemia in
the ‘‘APOþHG’’ protocol provides adequate lag time for
the activation of apocynin, thus enabling it to be effective
in the inhibition of NADPH oxidase.
Significance and Limitation of the Study
The present study clearly shows that acute hyperglycemia
enhances oxidative stress and exacerbates MI. The cardio-
protective effect of MPG is manifest even when the com-
pound is given at the time of reperfusion. This has
important clinical implications because it demonstrates
that it may be possible to intervene with antioxidants to re-
duce infarct size in cardiac patients undergoing cardiopul-
monary bypass or in medical patients with acute MI
undergoing percutaneous coronary intervention or throm-
bolysis by the simple administration of a potent antioxidant.
Although NADPH oxidase plays a critical role in hypergly-
cemia-induced oxidative stress, the clinical application of in-
hibitor of NADPH oxidase is not practical inasmuch as it has
to be used before the onset of hyperglycemia. However,
further experiments are needed to define its role when it is
administered before or early during ischemia.
CONCLUSION
The current study indicates that acute hyperglycemia
enhances oxidative stress during reperfusion, which in turn
exacerbates myocardial infarct size in nondiabetic mice. Po-
tent antioxidants can protect the heart against the hypergly-
cemic exacerbation of infarct size. The efficacy of apocynin
indicates that hyperglycemia-induced oxidative stress is me-
diated by the activation of NADPH oxidase. Finally, this
study provides direct evidence showing that the deleterious728 The Journal of Thoracic and Cardiovascular Sueffects of hyperglycemia on infarct size can be completely
reversed in a practical and clinically relevant manner.
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